Drug Profile
Antithrombin gamma - Kyowa Kirin
Alternative Names: Acoalan; Antithrombin III recombinant - Kyowa Kirin; KW-3357Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Kirin
- Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics; Immunoglobulins; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Antithrombin III deficiency; Disseminated intravascular coagulation
Most Recent Events
- 30 Sep 2023 Antithrombin gamma is still in phase I trials for Disseminated-intravascular-coagulation in European Union (IV, Injection)
- 30 Sep 2023 Antithrombin gamma is still in phase I trials for Antithrombin-III-deficiency in Sweden, France, Italy, and Germany (IV, Injection)
- 30 Sep 2023 Discontinued - Phase-III for Antithrombin III deficiency in Japan (IV) (prior to September 2023)